Overview

* Sotera Health Q2 2025 net revenues up 6.4% to $294 mln, beating estimates

* Adjusted EPS rises to $0.20, exceeding analyst expectations, per LSEG data

* Adjusted EBITDA grows 9.8% to $151 mln, surpassing estimates, per LSEG data

Outlook

* Sotera Health ( SHC ) raises full-year 2025 net revenue growth to 4.5%-6.0%

* Company expects full-year Adjusted EBITDA growth of 6.0%-7.5%

* Sotera Health ( SHC ) sees Adjusted EPS range at $0.75-$0.82

* Capital expenditures forecast lowered to $170 mln-$180 mln

Result Drivers

* STERIGENICS VOLUME - Strong volume performance at Sterigenics contributed to revenue growth

* NELSON LABS MARGIN - Margin expansion driven by improvements at Nelson Labs

* FAVORABLE PRICING - Revenue growth supported by favorable pricing across segments

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $294.34 $275.90

Revenue mln mln (6

Analysts

)

Q2 Beat $0.2 $0.17 (7

Adjusted Analysts

EPS )

Q2 Net $7.96

Income mln

Q2 Beat $151 mln $137.20

Adjusted mln (6

EBITDA Analysts

)

Q2 Miss $18.90 $74.20

Pretax mln mln (5

Profit Analysts

)

Q2 Gross $166.62

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for Sotera Health Co ( SHC ) is $15.50, about 27.6% above its August 7 closing price of $11.22

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)